Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis.
about
Apatinib for molecular targeted therapy in tumorGROα overexpression drives cell migration and invasion in triple negative breast cancer cells.β-TrCP1 degradation is a novel action mechanism of PI3K/mTOR inhibitors in triple-negative breast cancer cells.Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trialChemotherapy of metastatic triple negative breast cancer: Experience of using platinum-based chemotherapyDexamethasone induces docetaxel and cisplatin resistance partially through up-regulating Krüppel-like factor 5 in triple-negative breast cancer.Metastatic triple negative breast cancer: Optimizing treatment options, new and emerging targeted therapies.A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer.Effect of antitumor treatments on triple-negative breast cancer patients: A PRISMA-compliant network meta-analysis of randomized controlled trials.Outcomes research examining treatments, quality of life and costs in HER2-negative and triple-negative metastatic breast cancer: a systematic literature review.Pattern of metastatic spread and subcategories of breast cancer.Weekly paclitaxel, capecitabine, and bevacizumab with maintenance capecitabine and bevacizumab as first-line therapy for triple-negative, metastatic, or locally advanced breast cancer: Results from the GINECO A-TaXel phase 2 study.
P2860
Q26775828-350FBE5B-6D1D-4350-A1DB-1CE0DB9FB882Q33858488-A623FCFA-355B-4890-AC86-B99CC6C1753DQ35137658-80AB236A-9F67-4A79-9F8C-8090E3E23293Q36379813-FDBB7780-BD9B-47FE-B50C-0329E015927DQ36619151-C6E18A02-7167-4D63-86D5-62AAB8806DA4Q37706950-D2D832A8-982E-4664-98FE-33F9D665F38AQ38641240-CA6C2018-49DD-4305-960B-230DB3D01D40Q41709095-3618A1A0-412A-454E-B72C-B7D440CDEBCDQ47121796-9679C904-544C-47DE-8738-58E2E16DED72Q47206456-CC535B61-73C5-4AFB-BF51-B27F0286C9CCQ50550387-58C84CED-DC65-4F28-8A01-ED34081C292AQ51643519-528D4DD7-8FF0-48E5-A9A9-AB56D0B39C47
P2860
Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Targeted therapy in triple-neg ...... atic review and meta-analysis.
@en
Targeted therapy in triple-neg ...... atic review and meta-analysis.
@nl
type
label
Targeted therapy in triple-neg ...... atic review and meta-analysis.
@en
Targeted therapy in triple-neg ...... atic review and meta-analysis.
@nl
prefLabel
Targeted therapy in triple-neg ...... atic review and meta-analysis.
@en
Targeted therapy in triple-neg ...... atic review and meta-analysis.
@nl
P2093
P2860
P356
P1433
P1476
Targeted therapy in triple-neg ...... atic review and meta-analysis.
@en
P2093
Luciano Paladini
Mariana Bhering Andrade Ferreira
Otávio Clark
Tobias Engel Ayer Botrel
P2860
P356
10.2147/CE.S52197
P407
P577
2014-01-06T00:00:00Z